Open an account

Evogene

EVGN · NASDAQ

$0.3716+$0.0036 (+0.98%)TodayMarket closed ·
Prev close $0.368

About EVGN

Evogene Ltd. engages in the development and commercialization of a computer-biological platform for improving the development processes of products in the field of life sciences. The company is headquartered in Rehovot, Central(Hamerkaz) and currently employs 142 full-time employees. The company went IPO on 2007-06-11. Leveraging Big Data and Artificial Intelligence while incorporating a deep understanding of biology, Evogene established its technology, the Computational Predictive Biology (CPB) platform, to computationally design microbes, small molecules and genes as the core components for life-science products. Evogene holds a number of subsidiaries utilizing the CPB platform, for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits and ag-solutions for castor oil production.

Employees
142
Headquarters
Rehovot, Central(HaMerkaz)
Listed
Jun 11, 2007
Sector
Health Care
Industry
Biotechnology
Website
evogene.com

EVGN key statistics

Market cap
5.87M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
3.64M
Volume
11.12K
Open price
$0.39
High today
$0.39
Low today
$0.3695
52 Week high
$1.33
52 Week low
$0.3452

Evogene (EVGN) at a glance

As of Oct 20, 2026, Evogene (EVGN) shares are priced at $0.3716, giving the company a market cap of 5.87M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $0.3695 and $0.39. The current price is 0.6% above the day's low and 4.7% below its high.

Volume so far is 11.12K shares, below the average of 3.64M shares a day.

Over the past year Evogene has ranged from $0.3452 to $1.33, and now sits 3% of the way up that range.

Evogene met or beat analyst EPS estimates in 5 of the last 8 quarters. In Q2 FY26 it reported -$0.14 per share against an estimate of -$0.2754.

EVGN earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 5 of the last 8 quarters, by 76.8% on average.

  1. Q3 FY24: reported -$1.31 per share against an estimate of -$1.03
  2. Q4 FY24: reported $0.06 per share against an estimate of -$0.7395
  3. Q1 FY25: reported -$0.38 per share against an estimate of -$0.4641
  4. Q2 FY25: reported -$0.62 per share against an estimate of -$0.6426
  5. Q3 FY25: reported $0.44 per share against an estimate of -$0.4182
  6. Q4 FY25: reported -$0.61 per share against an estimate of -$0.2652
  7. Q1 FY26: reported -$0.60 per share against an estimate of -$0.2754
  8. Q2 FY26: reported -$0.14 per share against an estimate of -$0.2754

EVGN news

  • Press releasePRNewswire

    Evogene to Participate in U.S. East Coast AI Drug Discovery Roadshow Organized by the Israel Export Institute and TradeIL

  • Press releasePRNewswire

    Evogene and Pure Capital Group Reach Cooperation Agreement to Resolve Differences and Reconstitute Board of Directors

  • Press releasePRNewswire

    Evogene Reports Nasdaq Grants Additional 180-Day Period to Regain Minimum Bid Price Compliance

  • Press releasePRNewswire

    Evogene Responds to Dissident Shareholders: Transformation and Commercial Progress Provide a Clear Path Forward

  • Press releasePRNewswire

    Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Evogene Ltd. Shareholders Vote "FOR" the Company's Slate of Highly Qualified Director Nominees

  • Press releasePRNewswire

    Evogene Reports Second Quarter and First Half 2026 Financial Results

  • Press releasePRNewswire

    Evogene Chairman Nir Nimrodi to Join Quarterly Results Call to Address Current Dissident Shareholders Situation

  • 12 Health Care Stocks Moving In Monday's Pre-Market Session

Similar companies

Companies in the same industry as Evogene

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.